Portola's andexanet alfa and Boehringer Ingelheim's idarucizumab are both due to be filed for approval this year, with big potential implications for novel oral anticoagulants.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Jones, D. Anticoagulant antidotes start yielding Phase III promise. Nat Rev Drug Discov 14, 5–6 (2015). https://doi.org/10.1038/nrd4527
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd4527
This article is cited by
-
Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy
Journal of Thrombosis and Thrombolysis (2018)
-
FDA approves anticoagulant antidote
Nature Reviews Drug Discovery (2015)
